# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JP Morgan analyst Chris Schott maintains Eli Lilly and Co (NYSE:LLY) with a Overweight and raises the price target from $900...
Jim Cramer has identified eight companies that could potentially reach a market cap of $1 trillion, including Elon Musk's T...
Barclays analyst Carter Gould maintains Eli Lilly and Co (NYSE:LLY) with a Overweight and raises the price target from $913 ...
Shares of Eli Lilly And Company (NYSE: LLY) are moving higher on Wednesday. Here's what you need to know.
The Federal Trade Commission is preparing to sue the largest three pharmacy-benefit managers over their tactics for negotiating...
A study shows that only one in four U.S. patients prescribed Novo Nordisk's weight-loss drugs Wegovy or Ozempic remain on t...
https://www.dailymail.co.uk/health/article-13620101/ozempic-quitting-patients-weight-loss-effects.html?ns_mchannel=rss&ns_c...